Thalidomide in combination with Hydroxyurea in patients of Sickle Cell Anaemia- A Randomised Control Trial

Not Applicable

• Conditions: Health Condition 1: D570- Hb-SS disease with crisis

• Registration Number: CTRI/2023/05/052526
• Lead Sponsor: Dr Anindita Paul

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Written informed consent must be obtained prior to any screening procedures

2.Male patients aged 12 years and older and post menopausal female patients above 45 years on the day of signing informed consent.

3.Confirmed diagnosis of SCD by hemoglobin electrophoresis [performed in the hospital setting].

4.Patients with previous episodes of Vaso occlusive Crisis

5.Patients who havenâ??t been exposed to the use of HbF inducers other than HU

Exclusion Criteria

1.Female patients of child bearing age group

( 15 -45years)

2.Patients with liver, renal, cardiac, pulmonary or neurological deficits

3.History of thrombotic episodes

4.Patient with active HIV infection (detectable viral load)

5.Patients with active Hepatitis B infection (HBsAg positive)

6.Positive test for hepatitis C infection

Study & Design

• Study Type: Interventional
• Study Design: Not specified